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Abstract
Background: Mitochondrial DNA (mtDNA) mutations are reported in different tumors. However, there is no information on
the temporal development of the mtDNA mutations/content alteration and their extent in normal and abnormal mucosa
continuously exposed to tobacco smoke in lung cancer patients.
Methodology: We examined the pattern of mtDNA alteration (mtDNA mutation and content index) in 25 airway mucosal
biopsies, corresponding tumors and normal lymph nodes obtained from three patients with primary lung cancers. In
addition, we examined the pattern of mtDNA mutation in corresponding tumors and normal lymph nodes obtained from
eight other patients with primary lung cancers. The entire 16.5 kb mitochondrial genome was sequenced on Affymetrix
Mitochip v2.0 sequencing platform in every sample. To examine mtDNA content index, we performed real-time PCR
analysis.
Principal Findings: The airway mucosal biopsies obtained from three lung cancer patients were histopathologically
negative but exhibited multiple clonal mtDNA mutations detectable in the corresponding tumors. One of the patients was
operated twice for the removal of tumor from the right upper and left lower lobe respectively within a span of two years.
Both of these tumors exhibited twenty identical mtDNA mutations. MtDNA content increased significantly (P,0.001) in the
lung cancer and all the histologically negative mucosal biopsies except one compared to the control lymph node.
Conclusions/Significance:: Our results document the extent of massive clonal patches that develop in lifetime smokers and
ultimately give rise to clinically significant cancers. These observations shed light on the extent of disease in the airway of
smokers traceable through mtDNA mutation. MtDNA mutation could be a reliable tool for molecular assessment of
respiratory epithelium exposed to continuous smoke as well as disease detection and monitoring. Functional analysis of the
pathogenic mtDNA mutations may be useful to understand their role in lung tumorigenesis.
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Introduction
The human mitochondrial DNA (mtDNA) is a 16.5 kb double
stranded closed circular molecule which codes for the 12S and 16S
rRNAs, 22 tRNAs and 13 proteins essential for the mitochondrial
respiratory complex [1–2]. Most human cells contain hundreds of
copies of mitochondrial DNA (mtDNA) and nearly all of these
mtDNA copies are identical i.e. homoplasmic at birth [1–2].
Mutation rate in mtDNA is approximately 10 times higher than
nuclear genomic DNA (nDNA) [1]. To date, clonal mtDNA
mutations have been reported in different tumors [3]. There is
little information on the temporal development of these mutations
and their extent in normal and abnormal mucosa exposed to
tobacco smoke.
Lung cancer kills more than 1 million people worldwide with
smoking being the most important risk factor [4]. In the United
States, there were over 215,020 cases of lung cancer and an
estimated death of 161,840 in 2008 [4]. Despite significant
improvement in therapeutic modalities including surgery, plati-
num based chemotherapy and radiotherapy alone or in combi-
nation, the overall 5-year survival rate is only 15% [4]. Eighty-five
percent of lung cancers occur in tobacco smokers [4]. Moreover,
affected patients remain at significant risk for the development of
second primary tumor throughout their lifetime. Thus, develop-
ment of suitable methods for early disease detection, monitoring
and continuous evaluation of the airways in the patients with
primary lung cancer are of paramount importance.
In the present study, we examined the pattern of mtDNA
alteration (mutation and DNA content) in airway mucosal biopsies
obtained from follow up patients with primary lung cancers.
Corresponding tumors and normal lymph nodes were also
examined from these patients. All the biopsies appeared suspicious
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they were histologically negative. But the map of the mtDNA
alterations in these biopsies was striking and provided a unique
insight into the extent of mitochondrial dysfunction and increasing
risk of malignancy in patients who continue to smoke.
Results
Pattern of mtDNA mutation in the patients
Figure 1 shows the pattern of mtDNA mutations in patient 1.
This patient was operated twice within a span of two years on both
the lungs. The first tumor (T1) was surgically removed in 2002
from the right upper lobe followed by the removal of the second
tumor (T2) in 2004 from the left lower lobe. Five airway mucosal
biopsies were taken from the main carina (M1), right lower (M2
and M3) and left upper lobe (M4 and M5) surrounding the
primary tumor sites on both the lungs as depicted. The mucosal
biopsies were taken during the follow-up of this patient after
surgical removal of the second tumor from the left lower lobe. All
five mucosal biopsies were histopathologically without evidence of
dysplasia, and yet exhibited a range of 3–11 mtDNA mutations
(Fig. 1). A total of 16 mtDNA mutations were detected in the
mucosa of this patient. The first biopsy from the main carina
exhibited 3 mtDNA mutations (M1, Fig. 1A). The second biopsy
exhibited 5 mutations including 2 overlapping mutations with M1
(A2249C, A8341C, matched color, Fig. 1A–B). The third biopsy
exhibited 7 mtDNA mutations, including 3 overlapping mutations
with M2 (A3742C, G8836C and T15982G, matched color, Fig. 1B–
C). The fourth biopsy harbored 7 mtDNA mutations, including
overlapping mutations with M3 (A3742C, T3756C, G6035C,
G8836C and T15402A, matched color, Fig. 1A–D), M2
(A3742C, A8341C and G8836C, matched color, Figs. 2B and D)
and M1 (A8341C, matched color, Fig. 1A–D). The biopsy taken
adjacent to the tumor in the left lower lobe exhibited 11 mtDNA
mutations including overlapping mutations with M1 (A2249C,
T2516C and A8341C), M2 (A2249C, A8341C, G8836C and
T15982C), M3 (C4014A, G8836C and T15982G) and M4
(A8341C and G8836C) biopsies (Fig. 1A–E, matched color). Both
invasive tumors (T1 and T2) exhibited 20 identical mtDNA
mutations including all the 16 mutations detected in the
surrounding 5 normal mucosa (Fig. 1E–F) (Odds ratio
6.9610
10:1). Thirteen of these 20 (65%) mutations were in coding
regions (COI, COII, ATP6, ND1, ND4 and CYTB) and 7 (35%)
occurred in non-coding regions (12SrRNA, 16SrRNA, tRNA-
Lysine, D-loop) (Fig. 1, F, bottom rectangle). The additional 4
mutations detected in the tumors were represented in Fig. 1E
(Bottom rectangle, black, underlined). Two (G8836C and A8341C)
to three mtDNA mutations (A2249C, A3742C and T15982G) were
present in 4/5 and 3/5 mucosa respectively and in both tumors
(Fig. 1). Representative histological photomicrographs of the
mucosa and tumor are shown in Figs. 1A and 1F. Different color
codes correspond to a specific mutated mtDNA pattern showing
the clonal spread of the mtDNA mutation throughout the mucosa
and eventually given rise to the genetically related tumors
(Encircled).
In patient 2, five mucosal biopsies were obtained from the main
carina (M1), right lower lobe (M2 and M3) and right upper lobe
(M3 and M4) surrounding the primary tumor on the right lung as
shown in Figure 2. All the 5 lesions were histopathologically
normal as seen in patient 1 but exhibited a range of 2–8 mtDNA
mutations. The first lesion exhibited 2 mutations where as the
second one exhibited 3 with one identical mutation shared with
M1 (A10995C, Fig. 2A–B, matched color). The third lesion (M3)
exhibited 3 mtDNA mutations with one overlapping mutation
with M2 (A14917C) and M1 (G8836C) (Fig. 2A–C, matched color).
In the forth lesion (M4), 3 mutations were detected with one
overlapping mutation (G8836C) with M3 and M1 (Fig. 2A–D,
matched color). The fifth mucosal lesion (M5) exhibited 5
mutations including overlapping mutations of M4 (A3984C and
G8836C), M3 (A6831C, G8836C and A14917C), M2 (A14917C)
and M1 (G8836C) (Fig. 2A–E, matched color). The primary tumor
resected from the right upper lobe of this patient exhibited 9
mtDNA mutations including all the 8 mutations detected in the
surrounding 5 apparently normal mucosa specimens. All of these
mutations (9/9) were in the mitochondrial coding regions (ND1,
COI, ATP6, ND4, ND5 and CYTB) of the mtDNA (Fig. 2E,
bottom rectangle). The additional mutation (T7001C) detected in
the tumor is shown in Figure 2E (Bottom right rectangle, black,
underlined). One mtDNA mutation (G8836C) was present in 4/5
and another mutation (A14917C) was present in 3/5 mucosal
tissue samples (Fig. 2). Both of these mutations were also detected
in the corresponding tumor (Fig. 2E). Representative histological
photomicrographs of the mucosa and the tumor are shown in
Fig. 2A and E). Different color codes correspond to a specific
mutated mtDNA pattern showing the clonal spread of the mtDNA
mutation throughout the mucosa and eventually given rise to the
genetically related tumor (Encircled). Four mtDNA mutations
(G8836C, T3756C, A3984C and A7251C) were identical among
patients 1 and 2 (Fig. 1–2).
Patient 3 was a non-smoker with a bronchoalveolar carcinoma
and exhibited only 2 mtDNA mutations in the tumor (Table 1). No
mutation was detected in the normal mucosa. One margin with
metaplasia from this patient also did not show any mtDNA
mutation (Table 1). These results suggest a fundamental difference
in field cancerization and extent of clonal patches among a non-
smoker tumor. We sequenced 8 other patients for mtDNA
mutation and found a range of 1–9 mutations in the primary
tumors compared to the control, most of which were from the
coding regions of the mtDNA (Table 2). Other than somatic
mtDNA mutations, we also detected few germ line mtDNA
sequence variants in the tumors and corresponding mucosal
biopsies of all the patients (Table 3).
Alteration of mtDNA content in the lung cancer patients
We performed quantitative real-time PCR to determine
mtDNA content in patients’ mucosa, corresponding tumors, and
non-neoplastic lymph nodes. With only a single exception in one
biopsy (Patient 1, M1) mtDNA content was significantly higher
(P,0.001) in the lung cancer and all of the histologically normal
mucosal biopsies compared to the control lymph node (Fig. 3).
This was even true in the mucosa and metaplastic margin
identified in patient 3, the non-smoker (Fig. 4). MtDNA content
was increased without a corresponding mtDNA mutation (Fig. 4).
Thus, increased mtDNA content is a feature in extensive mucosal
fields from both smoking and non-smoking lung cancer patients.
Discussion
Mitochondrial DNA mutations are frequent in various tumor
types [3], and detected in preneoplastic lesions thereby indicating
their occurrence at early stages of multistage tumor progression
[5]. Detection of mtDNA mutation is easier and more reliable
compared to nuclear DNA because of their high copy number in
cancer cells [6–7]. Therefore, scrutinizing mtDNA mutations in a
small number of cells at different stages of tumor progression is
possible. In order to use mtDNA mutation as an unbiased tool for
detection of clonal cell populations, sequencing of the entire
mitochondrial genome is necessary and must be done together
Mitochondrial DNA Mutation
PLoS ONE | www.plosone.org 2 August 2009 | Volume 4 | Issue 8 | e6533Figure 1. Pattern of mtDNA mutation in patient 1. The patient was operated twice on 2002 and 2004 with removal of tumors from the right
upper (T1) and left lower lobe (T2) respectively. Five bronchoscopically abnormal airway mucosal biopsies were obtained following second surgery
(T2) of this patient from main carina (M1), right upper lobe (M2 and M3) and left lower lobe (M3 and M4) surrounding both the tumors as depicted
(Panel A–E). The mucosal biopsies exhibited a range of 3–11 mtDNA mutations as represented in different color (Panel A–E). Identical mutations are
shown in the same color in different biopsies and the tumor. A different color code was also used for each mucosa to indicate the clonal progression
of the lesions on both the lungs with accumulated mtDNA mutations. Representative histological photomicrograph of the mucosa and the tumor has
been shown in panel A and F. Both the tumors T1 and T2 exhibited twenty identical mtDNA mutations (E–F, Bottom rectangle) including all the 16
mutations exhibited by the five mucosal biopsies (Matched color). The additional 4 mtDNA mutations detected in the tumors are represented
underlined in black color in the bottom rectangle (Panel E–F). Two mtDNA mutations (G8836C and A8341C) were present in 4/5 and 3 other mutations
(A2249C, A3742C and T15982G) were present in 3/5 mucosal biopsies. Tumors are encircled to indicate their development from the clonal mucosal
patches. T1: Tumor from the right upper lobe; T2: Tumor from the left lower lobe; M: Mucosa.
doi:10.1371/journal.pone.0006533.g001
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PLoS ONE | www.plosone.org 3 August 2009 | Volume 4 | Issue 8 | e6533Figure 2. Pattern of mtDNA mutation in patient 2. The patient was operated on 2005 for surgical removal of tumor from the right upper lobe.
Five bronchoscopically abnormal airway mucosal biopsies were obtained from main carina (M1), right lower lobe (M2 and M3) and right upper lobe
(M3 and M4) surrounding the tumors as depicted (Panel A–E). The mucosal biopsies exhibited a range of 2–5 mtDNA mutations as represented in
different color (Panel A–E). Identical mutations are shown in same color in different biopsies and the tumor. A different color code was also used for
each mucosa to indicate the clonal progression of the lesions with accumulated mtDNA mutations. Representative histological photomicrograph of
the tumor and normal mucosa are shown in Panel A and D. The tumor exhibited 9 mtDNA mutations (Represented in the Bottom rectangle) including
all the 8 mutations exhibited by the five mucosal biopsies (Matched color). An additional mtDNA mutation (T7001C) detected in the tumor is
underlined in black in the bottom rectangle. Tumor was encircled to indicate its development from the clonal mucosal patches. M: Mucosa.
doi:10.1371/journal.pone.0006533.g002
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polymorphic nature of the mtDNA [7]. In the present study,
amplification of considerable amount of mtDNA from very small
mucosal biopsies, tumor and corresponding normal tissues enabled
us to scan the whole mitochondrial genome. This was readily
accomplished on the Affymetrix high throughput Mitochip v2.0
sequencing platform previously shown to be a reliable tool for
detecting mtDNA mutation [5,8]. This recent version of Mitochip
(Compared to Mitochip v1.0) not only has a high sensitivity for
mutation detection spanning the entire mitochondrial genome but
also capable of determining heteroplasmic mtDNA mutation [8–
9]. The observed mutation can also be verified by conventional
sequencing. However, Mitochip v2.0 cannot detect small inser-
tion/deletion as it is designed primarily to detect mtDNA
mutation. The mutations detected in the present study were
somatic or germ line in nature and confirmed as not due to any
haplotypic variation [5,8–9]. Thus, all the de novo mutations
detected and reported in this study are associated with the tumor
phenotype.
In patient 1, small follow up biopsies were taken from areas of
the airway mucosa which appeared abnormal under Autofluores-
cence-Bronchoscopy. Although all the biopsies were histopatho-
logically negative and without dysplastic changes, they exhibited
multiple mtDNA mutations some of which were shared across
large tracks of the airway epithelium. These results demonstrate
the clonal spread of multiple mtDNA mutations throughout the
respiratory mucosa. Clonal spread of p53 mutation and microsat-
ellite alterations (LOH and MA) at multiple foci in normal
appearing bronchial epithelium has been reported earlier [10–12].
In the present study, dramatic expansion of mutant bronchial
epithelial clones was traceable through mtDNA mutation with
great precision and in an unbiased manner by sequencing the
entire mitochondrial genome in every sample.
It is likely that the biopsies contained heterogeneous patches of
cells with clonal alterations acquired by random mitochondrial
genetic drift [7]. As in patient 1, most of the clones shared a
number of identical mtDNA mutations along with additional
mutations necessary for the clonal expansion (Fig. 5). The fittest
clones harboring more advantageous mtDNA/nDNA mutations
progressed through the mucosa and eventually gave rise to two
apparently independent primary tumors that are nevertheless
surely linked by identical mtDNA mutations [7,13]. Detection of
all the mucosal mtDNA mutations in both the tumors resected
within a span of 2 years strongly supports their clonal origin.
Moreover, we have also shown that the two separate tumors from
the opposite lungs exhibited multiple identical mtDNA mutations;
the odds of this occurrence by chance are vanishingly low. The
first tumor probably developed from one of the more dominant
clones scattered on the right lung after acquiring the necessary
mtDNA/nDNA alterations sufficient to promote tumorigenesis.
The second tumor likely developed in the same way on the left
lung but acquired nDNA mutational hits several months later or
otherwise it could possibly be a pulmonary metastasis. The data
from patient 2 also support the extensive clonal spread of mtDNA
mutations and subsequent tumor development after acquiring
sufficient mtDNA and/or nDNA changes. A high-resolution
genome wide analysis of these biopsies and corresponding tumors
revealed clonal alteration of a number of key nDNA encoded
genes in these patients (Unpublished observation) further support-
ing this notion. However, due to unavailability, we could not
examine the pattern of mtDNA alteration spectrum in a relatively
large number of patients.
Table 1. Pattern of mtDNA mutation in patient 3.
Nucleotide
position RCRS
1
Normal
(Lymph node)
Mucosa
(Pooled)
2
Negative
for tumor
3 Metaplasia Tumor
Amino acid
change
mtDNA
region
15403 c c c c c t I-I CYTB
15809 g g g g g a A-T CYTB
1Revised Cambridge Reference Sequence;
2Mucosal biopsies from 5 different regions were pooled together because of small sample size;
3Tumor adjacent histologically normal margin.
doi:10.1371/journal.pone.0006533.t001
Table 2. Pattern of somatic mtDNA mutation in the 8 lung cancer patients.
Nucleotide Position RCRS
1 Normal
2 Tumor Amino acid change mtDNA region
194 t t c - D-loop
920 t t c - D-Loop
5326 c c a T-D ND2
8494 t t a A-D ATP8
9115 t t g L-V ATP6
10871 t t c P-S ND4
13442 t t g T-S ND5
14831 a a c A-P CYTB
15551 g g a L-E CYTB
1RCRS: Revised Cambridge Reference Sequence;
2Normal Lymphocytes.
doi:10.1371/journal.pone.0006533.t002
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was suggested as an indicator of a high susceptibility genetic
background which might facilitate concomitant somatic mutationin
mtDNA and nDNA [14]. Detection of clonal germ line sequence
variants and simultaneous somatic mtDNA mutations in tumors
and mucosa of the lung cancer patients strongly support this notion.
Pathogenic mtDNA mutations may indicate for their functional
contribution in progression of the tumors. Among the mtDNA
mutations observed in these patients, the coding G8836C (ATP6)
mutation is recently reported in patients with Leber Hereditary
Optic Neuropathy (LHON)-like syndrome and thyroid tumors [15–
16]. The interspecies conservation of this nucleotide is high and this
mutation has been predicted to be pathogenic [15]. Notably, this
mtDNA mutation was detected in 8/10 mucosal biopsies and all 3
tumors examined from both the patients supporting a functional
contribution in tumorigenesis. However, further functional analysis
is necessary to draw a more definitive conclusion.MtDNAmutation
at identical nucleotide position among different lung and kidney
cancer patients were reported earlier [16]. In the light of a
pathogenic/contributing mtDNA mutation, a specific mtDNA
mutation appeared to have been selected in different tumor types.
We made similar observation in this present study and thus,
occurrence of the pathogenic G8836C and other identical mtDNA
mutations observed among different lung cancer patients are
unlikely to be due to sample contamination. Notably, the G8836C
pathogenic mtDNA mutation detected in LHON and thyroid
cancer[15–16] and frequentlyinourstudyindicatesfora functional
role in lung cancer progression.
Most of these mutations were found in the coding regions of the
mtDNA which could potentially lead to a disruption of the
respiratory complex and result in an increase in Reactive Oxygen
Species (ROS). Recent studies have shown that mtDNA mutations
lead to an increase in ROS and promote tumor cell growth,
proliferation and metastasis [17–20]. One study has shown an
increase in mtDNA copy number in lung fibroblasts as an early
event in response to oxidative stress [21]. Recently, an increase in
mtDNA content was identified with aging and smoking associated
lung-tissues and primary head and neck squamous cell carcinomas
[22–23]. Histologically negative mucosal biopsies as well the
tumors of both the patients exhibited significantly elevated level of
mtDNA content. Thus, it appears that with the evolution of
homoplasmic mtDNA mutation and clonal spread, mtDNA
Table 3. The pattern of germ line mtDNA sequence variants in the lung cancer patients.
Nucleotide position RCRS
1 Normal
2 Tumor Mucosa Amino acid change mtDNA region Remark
72 a gg g- D-Loop R
3
2705 a gg g- 16SrRNA N
7026 c tt tA-S COI R
8185 g cc cC-C COII N
11445 g aa aM-K ND4 N
11465 a gg gL-V ND4 R
15563 t cc cY-H CYTB N
1Revised Cambridge Reference Sequence;
2Matched normal lymphocytes;
3R: Reported; N: Novel as per Human Mitochondrial Database and relevant literature.
doi:10.1371/journal.pone.0006533.t003
Figure 3. MtDNA content in the lung cancer patients. mtDNA
content was measured by multiplex real-time PCR using nuclear
encoded b-actin and mitochondria encoded COI gene. A ratio of COI/b -
actin corresponds to the fold difference compared to control. MtDNA
content increased significantly (P,0.001) in the mucosal biopsies and
corresponding tumors compared to the normal control in both the
patients as indicated. N: Normal lymph node; M: Mucosa; T: Tumor. *P
value ,0.05 compared to normal lymph node.
doi:10.1371/journal.pone.0006533.g003
Figure 4. mtDNA content index in patient 3. mtDNA content
increased significantly (P,0.05) in the mucosa (M), adjacent normal (NT)
and in the metaplastic margin (MT) compared to normal lymph node
used a s control.
doi:10.1371/journal.pone.0006533.g004
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G8836C) were identical in both the patients who were regular
smokers, suggesting the effects of common targets from tobacco
carcinogens on mtDNA. The high frequency of mtDNA mutations
among smokers also suggests a key role for early mitochondrial
genetic changes in the progression of their tumors.
In the present study, clonal progression of histologically normal
appearing respiratory mucosa into tumor was traceable through
mtDNA mutations. This is the most definitive study to
demonstrate that the 2 tumors in the opposite locations in one
patient (Patient 1) are clonally related. However, we could not
examine more follow up patients due to the lack of bio-specimens.
Documentation of these extensive clonal populations with mtDNA
mutations sheds light on the challenges of early detection
approaches. Moreover, targeting these mtDNA mutations may
be helpful based on molecular detection in sputum and blood
DNA in chemoprevention approaches and new biologic thera-
peutics. Further functional analysis of the common mtDNA
mutations will allow us to better understand their specific role in
cancer progression and chemoresistance.
Materials and Methods
Patients’ history and lung specimens
Three follow-up lung cancer patients were examined for mtDNA
mutation with signed informed consent in a Johns Hopkins IRB
approved protocol. Patient 1 was a 75 year old female who
underwent a right upper lobectomy in 2002 for a stage IIB poorly
differentiated squamous cell carcinoma (T3N0MX). In 2004, she
underwent a left lower lobectomy for a second stage IIB (T2N0MX)
squamous cell carcinoma. Patient 2 was a 58 year old man, who in
2005 underwent a right upper lobectomy for a stage IA (T1N0MX)
moderately differentiated squamous cell carcinoma. Both patients
were regular smokers for more than 10 years. Patient 3 was a 48
years old female who underwent a right upper lobectomy for a stage
IA (T1N0MX) bronchioloalveolar carcinoma. This patient was a
non-smoker. During follow-up, airway mucosal biopsies were taken
from areas suspicious for mild to moderate to severe dysplasia or
carcinoma in situ (CIS) based on Auto-Fluorescence-Bronchoscopy
(R.Y. and J.B.). All the biopsy specimens were taken at the same
time. Biopsies were histologically evaluated by a lung pathologist
(W.H.W). The surgically resected lung tumors were also obtained
from eachpatient. As a control, matchednormallymph node free of
tumor was used in each case. In addition, we also sequenced
matched normal and tumor tissues from 8 other lung cancer
patients (Table 4).
Mitochondrial whole genome amplification and
sequencing
Genomic DNA was extracted according to our standard protocol
from the microdissected tumor tissues and other specimens [5].
We amplified whole mitochondrial genomic DNA from 10 ng of
Figure 5. MtDNA genetic mutation tree in patient 1. Possible clonal evolution of the lung tumors has been depicted. Each mucosal biopsy
(Circled, M1-M5) shared some identical mtDNA mutations (Matched color) along with additional mutations in the heterogeneous mucosal field. The
fittest clones emerged in the primary tumors (T1-T2) with the more selective mtDNA mutations (Total 20 mtDNA mutations, 16 were shared between
M1-M5 as in Figure 1).
doi:10.1371/journal.pone.0006533.g005
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amplification kit according to the manufacturer’s protocol as
described earlier [8]. The amplified DNA was then purified using
DNA MiniAmp Cleaning kit (Qiagen, Valencia). We examined the
purity of the amplified mtDNA and nuclear DNA contamination
by PCR analysis using primer specific for mitochondria encoded
COXI/COXII and nuclear encoded b-actin. Four to five hundred
nanogram of purified mtDNA was used for sequencing on the
Affymetrix MitochipV2.0 platform [5,8].
Mitochip v2.0 sequencing array analysis
We performed fragmentation, labeling and Chip hybridization
of the mtDNA as per Affymetrix protocol with appropriate
controls as described earlier [5,8]. Data analysis was performed
using Affymetrix GSEQ software and the Revised Cambridge
Reference Sequence (RCRS) was used as reference sequence [24].
The MitoAnalyzer software was also utilized to verify the mtDNA
mutations at different nucleotide positions as described earlier
[5,8].Somatic mutations were identified as base pair changes in
mtDNA when compared to normal mtDNA sequence found in
lymph nodes free of tumor. Germ line mutations were identified as
base pair changes present in the normal lymphocytes as well as
tumor tissues and/or margin samples compared to the RCRS
[14]. A germ line sequence variant was designated as novel when
absent in the human mitochondrial database and other relevant
studies in the same haplogroups [14,25]. Sequence variants
previously reported in different diseases including cancer are
designated as pathogenic [14,25].
Quantitative real-time PCR
To examine mtDNA content, we used the 7900HT sequence
detection system (Applied Biosystems, Foster City, CA) to amplify
nuclear DNA (nDNA) encoded b-Actin and mtDNA encoded
Cytochrome C oxidase I (COI) using genomic DNA template as
described earlier [26].
Statistical analysis
Student’s t-test was performed to determine the statistical
significance. P value less than 0.05 was considered significant. All
P values generated were two sided.
Odds ratio
The odds of 20 random identical mtDNA mutations occurring
by chance in two separate tumors localized in the opposite lungs of
the same patient were calculated as [(genome size)6(mutations)]6
[(genome size)6(mutations)] i.e. [16,499:1620]6[16,499:1620]
=6.9610
10:1 [27].
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